VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy

Mise à jour : Il y a 4 ans
Référence : NCT00210327

Femme et Homme

  • | Pays :
  • Switzerland
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of this study is to assess the antitumor activity (in terms of overall response rate - ORR - i.e. sum of complete and partial responses)of bortezomib in pretreated MALT lymphomas with one prior sistemic therapy regimen


Critère d'inclusion

  • Lymphoma, Mucosa-Associated Lymphoid Tissue

Liens